Author's posts
Keck Medicine of USC taps finance leader
Los Angeles-based Keck Medicine of USC has appointed Mika Taylor chief of financial planning and analysis for the health system.
CommonSpirit exec exits for new CEO role
E.J. Kuiper, CEO of Chicago-based CommonSpirit Health’s Midwest division, is leaving his post to helm Franciscan Missionaries of Our Lady Health System in Baton Rouge, La.
For 1st time, state board sets a drug price ceiling
On Feb. 23, Colorado secured a national first by agreeing to establish a price ceiling on a medication, The Denver Post reported.
Texas Hospital Association leader: More needed to help state's rural hospitals
A recent report from Chartis, a healthcare advisory services firm, found that 45 Texas rural hospitals are at risk of closure. The state’s total composes the highest percentage of the 418 rural hospitals in the U.S. at the risk of closure.
The nationwide push to address violence against healthcare workers: 4 updates
Amid violence against healthcare workers, hospitals, health systems and states across the U.S. are working to address the issue. These efforts range from appointing “workplace violence coordinators” to holding a gun violence prevention forum.
Pennsylvania hospital to join WellSpan Health
Lewisburg, Pa.-based Evangelical Community Hospital is set to join York, Pa.-based WellSpan Health pending regulatory approval.
Health systems getting new EHRs
Here are four hospitals and health systems that have implemented new EHR systems or announced plans to do so since Jan. 30:
Health systems getting new EHRs
Here are four hospitals and health systems that have implemented new EHR systems or announced plans to do so since Jan. 30:
FDA revokes approval of cancer drug Pepaxto
More than two and a half years after the FDA warned about an increased risk of death linked to Pepaxto, a multiple myeloma drug, the agency withdrew the medication’s approval Feb. 23.
FDA revokes approval of cancer drug Pepaxto
More than two and a half years after the FDA warned about an increased risk of death linked to Pepaxto, a multiple myeloma drug, the agency withdrew the medication’s approval Feb. 23.
